Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 58 of 1219 for:    arthritis+management

Representation and Medication Use in Juvenile Idiopathic Arthritis (RUMAJI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03892135
Recruitment Status : Completed
First Posted : March 27, 2019
Last Update Posted : April 29, 2019
Sponsor:
Collaborators:
Research department, unknowns, Strategic & innovation consulting, Paris (anthropologists)
NORDIC pharma (funding)
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:
According to the International League of Associations for Rheumatology classification, Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of arthritis of unknown cause and with onset before 16 years of age, characterized by joint inflammation lasting for 6 or more weeks. Few studies exist regarding the care experience of children affected by this rheumatic condition. On the other hand, methotrexate and biologics constitute the primary treatment for children with JIA. As with adults undergoing the same treatment, adherence is critical. Difficulties for children to take the drugs have been reported. Notwithstanding, if adherence promotion in pediatric chronic conditions has been the subject of recommendations with regard to care management, the investigators lack information to understand the grounds for adherence specifically in JIA. In order to understand and decipher the parent-child adherence mechanisms and practices, the RUMAJI study will be conducted. Indeed, improving the relational approach between children and their caregivers as well as unrestricted drug adherence involves researching and understanding how appropriation of the disease and treatment could be achieved.

Condition or disease Intervention/treatment
Juvenile Idiopathic Arthritis Other: Interviews with parents of children with juvenile idiopathic arthritis Other: Interviews with children with juvenile idiopathic arthritis Other: Interviews with Physicians

Layout table for study information
Study Type : Observational
Actual Enrollment : 36 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: Representation and Medication Use in Juvenile Idiopathic Arthritis - RUMAJI
Actual Study Start Date : April 1, 2017
Actual Primary Completion Date : October 1, 2017
Actual Study Completion Date : December 1, 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Physicians
3 paediatricians and 3 rheumatologists
Other: Interviews with Physicians
Interviews with Physicians

Parents
Parents
Other: Interviews with parents of children with juvenile idiopathic arthritis
Interviews with parents of children with juvenile idiopathic arthritis

Children
Children
Other: Interviews with children with juvenile idiopathic arthritis
Interviews with children with juvenile idiopathic arthritis




Primary Outcome Measures :
  1. Interview with parents [ Time Frame: 1 day ]
    Interview with parents to learn about role of parents in the management of juvenile idiopathic arthritis in their children


Secondary Outcome Measures :
  1. Interview with children [ Time Frame: 1 day ]
    Interview with children to learn about role of children in the management of their juvenile idiopathic arthritis

  2. Interview with physicians [ Time Frame: 1 day ]
    Interview with physicians to learn about role of physicians in the management of juvenile idiopathic arthritis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children with JIA and their parents
Criteria

Inclusion criteria:

  • all JIA forms
  • all treatment type (NSAIDs, MTX, bDMARDs)

Exclusion criteria:

- none


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03892135


Locations
Layout table for location information
France
Uhmontpellier
Montpellier, France, 34295
Sponsors and Collaborators
University Hospital, Montpellier
Research department, unknowns, Strategic & innovation consulting, Paris (anthropologists)
NORDIC pharma (funding)
Investigators
Layout table for investigator information
Principal Investigator: Jean-David COHEN, MD University Hospital, Montpellier

Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT03892135     History of Changes
Other Study ID Numbers: RECHMPL19_0171
First Posted: March 27, 2019    Key Record Dates
Last Update Posted: April 29, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: NC

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University Hospital, Montpellier:
Role of parents, children and physician
Qualitative
Interview
Juvenile idiopathic arthritis
Adherence
mechanisms of adherence in juvenile idiopathic arthritis

Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases